Pharmaceutical Antitrust: Concerted Conduct - Pay for Delay
Pay-for-delay in the pharmaceutical industry occurs when a branded drug manufacturer settles a dispute with a generic competitor, with the effect of delaying the latter’s entry in the market. While judicial settlements are not unlawful per se, they can raise significant issues under antitrust rules and have given rise to a lot of enforcement action in recent years. In this video, Shari Lahlou, Laurence Bary and George Gordon discuss rising antitrust concerns in the U.S. and EU and notable court cases involving pay-for-delay related offenses, as well as the consequences of these types of agreements on consumer pricing and drug availability. For more information, visit: https://bit.ly/3T8xy1d